An Open-label, Dose-escalation, Safety and Pharmacokinetics Phase I Study of Ombrabulin in Combination With Docetaxel and Cisplatin Every 3 Weeks in Patients With Advanced Solid Tumors.

Trial Profile

An Open-label, Dose-escalation, Safety and Pharmacokinetics Phase I Study of Ombrabulin in Combination With Docetaxel and Cisplatin Every 3 Weeks in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2011

At a glance

  • Drugs Cisplatin; Docetaxel; Ombrabulin
  • Indications Lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 05 Jul 2011 Planned end date changed from 1 Apr 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top